succinamide, GLU glucose, PPB plasma protein binding, CL - clearance, AUC- N-hydroxy – – – area under the curve, TI therapeutic index, hERG - human Ether-à-go-go-Related Gene, NC – – not calculated, ND not determined, ID identification, M metabolite, SD Sprague Dawley, – – – – HPLC High performance liquid chromatography, TLC thin layer chromatography, DMSO – – – dimethyl sulfoxide, NADPH - nicotinamide adenine dinucleotide phosphate, MTT - bromide, DMEM - Dulbecco's Modified Eagle's Medium, FBS fetal bovine serum, HEPES - (4-(2-hydroxyethyl)-1-piperazineethanesulfonic – acid, FCS fetal calf serum, TEER - trans-epithelial electrical resistance, HBSS Hank’s – – balance salt solution, LC-MS Liquid chromatograph-mass spectrometry. – REFERENCES 1. World Health Organisation. 20th Global Tuberculosis Report 2015: Executive Summary, ed.; Geneva, Switzerland, 2015; pp 1-4. 2. Streicher, E. M.; Müller, B.; Chihota, V.; Mlambo, C.; Tait, M.; Pillay, M.; Trollip, A.; Hoek, K. G. P.; Sirgel, F. A.; Gey van Pittius, N. C.; van Helden, P. D.; Victor, T. C.; Warren, R. M. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) in South Africa. 2012, 686-694. Infect. Genet. Evol. 12, 3. Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The challenge of new drug discovery for tuberculosis. 2011, 483-490. Nature 469, 4. Goel, D. Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis. J. 2014, 76-78. Pharmacol. Pharmacother. 5,
– N-hydroxy succinamide, GLU – glucose, PPB – plasma protein binding, CL - clearance, AUC- area under the curve, TI – therapeutic index, hERG - human Ether-à-go-go-Related Gene, NC – not calculated, ND – not determined, ID – identification, M – metabolite, SD – Sprague Dawley, HPLC – High performance liquid chromatography, TLC – thin layer chromatography, DMSO – dimethyl sulfoxide, NADPH - nicotinamide adenine dinucleotide phosphate, MTT - bromide, DMEM - Dulbecco's Modified Eagle's Medium, FBS – fetal bovine serum, HEPES - (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, FCS – fetal calf serum, TEER - trans-epithelial electrical resistance, HBSS – Hank’s balance salt solution, LC-MS – Liquid chromatograph-mass spectrometry. REFERENCES 1. World Health Organisation. Global Tuberculosis Report 2015: Executive Summary, 20th ed.; Geneva, Switzerland, 2015; pp 1-4. 2. Streicher, E. M.; Müller, B.; Chihota, V.; Mlambo, C.; Tait, M.; Pillay, M.; Trollip, A.; Hoek, K. G. P.; Sirgel, F. A.; Gey van Pittius, N. C.; van Helden, P. D.; Victor, T. C.; Warren, R. M. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) in South Africa. Infect. Genet. Evol. 2012, 12, 686-694. 3. Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The challenge of new drug discovery for tuberculosis. Nature 2011, 469, 483-490. 4. Goel, D. Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis. J. Pharmacol. Pharmacother. 2014, 5, 76-78.